Corvus Pharmaceuticals Inc (NASDAQ:CRVS) — Market Cap & Net Worth
Market Cap & Net Worth: Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has a market capitalization of $1.12 Billion ($1.12 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8305 globally and #2425 in its home market, demonstrating a -3.07% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Corvus Pharmaceuticals Inc's stock price $13.26 by its total outstanding shares 84090424 (84.09 Million). Review CRVS current and long-term liabilities to assess the company's total debt and financial obligations.
Corvus Pharmaceuticals Inc Market Cap History: 2016 to 2026
Corvus Pharmaceuticals Inc's market capitalization history from 2016 to 2026. Data shows change from $1.20 Billion to $1.12 Billion (-0.69% CAGR).
Index Memberships
Corvus Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.05% | #243 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #911 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.06% | #141 of 263 |
Weight: Corvus Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Corvus Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Corvus Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CRVS by Market Capitalization
Companies near Corvus Pharmaceuticals Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Corvus Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Corvus Pharmaceuticals Inc Historical Marketcap From 2016 to 2026
Between 2016 and today, Corvus Pharmaceuticals Inc's market cap moved from $1.20 Billion to $ 1.12 Billion, with a yearly change of -0.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.12 Billion | +72.21% |
| 2025 | $647.50 Million | +43.93% |
| 2024 | $449.88 Million | +203.98% |
| 2023 | $148.00 Million | +107.06% |
| 2022 | $71.48 Million | -64.73% |
| 2021 | $202.66 Million | -32.30% |
| 2020 | $299.36 Million | -34.56% |
| 2019 | $457.45 Million | +48.23% |
| 2018 | $308.61 Million | -64.58% |
| 2017 | $871.18 Million | -27.55% |
| 2016 | $1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Corvus Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.12 Billion USD |
| MoneyControl | $1.12 Billion USD |
| MarketWatch | $1.12 Billion USD |
| marketcap.company | $1.12 Billion USD |
| Reuters | $1.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more